<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03073356</url>
  </required_header>
  <id_info>
    <org_study_id>1-10-72-316-16</org_study_id>
    <nct_id>NCT03073356</nct_id>
  </id_info>
  <brief_title>Ketones in Heart Failure - Effects on Cardiac Efficiency</brief_title>
  <official_title>Effects of Ketones on Cardiac Function and Oxygen Consumption in Heart Failure Patients With Reduced Ejection Fraction and Healthy Test Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ketones may have beneficial effects on myocardial metabolism and hemodynamics. In the present
      study, healthy test subjects and patients with heart failure with reduced ejections fraction
      will be investigated in a randomized cross-over design with ketone infusions and placebo.
      Myocardial efficiency and hemodynamics will be evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prevalence of patients with heart failure and reduced ejection fraction (HFrEF) is 1-2%,
      and the lifetime risk of heart failure at age 55 years is approximately 30%. Despite advances
      in treatment, hospitalization rate and mortality remains high. It is well known that
      myocardial metabolism changes during development of HFrEF, and may contribute to contractile
      dysfunction. However, the myocardium can be considered an omnivore regarding substrate
      utilization, conferring an important adaptive property. Hence, it metabolizes either glucose,
      lipids, lactate, amino acids or ketones (3-hydroxybutyrate) depending on substrate
      availability, hormonal status and cardiac demands. These substrates differ with regard to
      myocardial energy efficiency (MEE) (cardiac work related to oxygen consumption). Since high
      MEE is associated with a better prognosis in HFrEF, manipulating substrate uptake could be a
      new treatment modality in heart failure patients.

      Recently, it was shown that the human myocardium increases 3-hydroxybutyrate (3-OHB)
      metabolism during development of HFrEF. These changes may be beneficial as 3-OHB could
      increase myocardial efficiency and lower oxidative stress by scavenging free radicals.
      However, until now this has not been investigated in clinical trials, and the effect of 3-OHB
      on cardiac function, oxygen consumption and perfusion remains undetermined in HFrEF patients.

      In the present study the investigators will evaluate whether elevated circulating 3-OHB
      affect myocardial oxygen consumption, MEE and perfusion in healthy subjects and patients with
      HFrEF, and whether 3-OHB affect hemodynamics and contractile function.

      10 healthy test subjects and 20 HFrEF patients will be subjected to placebo and 3-OHB
      infusion in a randomized cross-over design. Acetate-PET, echocardiography and right sided
      heart catheterization will be applied.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 17, 2017</start_date>
  <completion_date type="Actual">November 16, 2017</completion_date>
  <primary_completion_date type="Actual">November 16, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized dobbel-blinded crossover</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial efficiency</measure>
    <time_frame>1 day</time_frame>
    <description>Based on myocardial PET examinations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiac output</measure>
    <time_frame>1 day</time_frame>
    <description>Right sided heart catheterization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myocardial perfusion</measure>
    <time_frame>1 day</time_frame>
    <description>Based on myocardial PET examinations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial oxygen consumption</measure>
    <time_frame>1 day</time_frame>
    <description>Based on myocardial PET examinations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary and wedge pressure</measure>
    <time_frame>1 day</time_frame>
    <description>Right sided heart catheterization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mixed venous saturation</measure>
    <time_frame>1 day</time_frame>
    <description>Right sided heart catheterization</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Heart Failure, Systolic</condition>
  <condition>Ketonemia</condition>
  <arm_group>
    <arm_group_label>Control - Healthy test subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Age matched subjects without symptoms of heart failure or ischemic heart disease N=10</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HFrEF - Heart failure patients investigated by PET</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with heart failure (HFrEF) N=12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HFrEF - Right heart catheterization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with heart failure (HFrEF) N=12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HFrEF - Right heart catheterization study 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose finding study (increasing dosage of 3-OHB)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infusion of 3-OHB</intervention_name>
    <description>Increase in 3-OHB levels</description>
    <arm_group_label>Control - Healthy test subjects</arm_group_label>
    <arm_group_label>HFrEF - Heart failure patients investigated by PET</arm_group_label>
    <arm_group_label>HFrEF - Right heart catheterization</arm_group_label>
    <arm_group_label>HFrEF - Right heart catheterization study 2</arm_group_label>
    <other_name>Na-3-OHB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infusion of placebo</intervention_name>
    <description>NaCl</description>
    <arm_group_label>Control - Healthy test subjects</arm_group_label>
    <arm_group_label>HFrEF - Heart failure patients investigated by PET</arm_group_label>
    <arm_group_label>HFrEF - Right heart catheterization</arm_group_label>
    <arm_group_label>HFrEF - Right heart catheterization study 2</arm_group_label>
    <other_name>NaCl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For participants with heart failure:

          -  Symptoms of Heart failure NYHA 2-3

          -  LVEF&lt;40%

        For all participants:

          -  Negative HCG for women in the pregnant age

        Exclusion Criteria:

          -  Significant cardiac valve disease

          -  Signs or history of major myocardial infarction (STEMI) within 3 months

          -  Other disease or treatment making subject unsuitable for study participation

          -  Treatment for diabetes or HbA1c level &gt;7%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roni R Nielsen, MD PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Cardiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of cardiology, Aarhus university hospital Skejby</name>
      <address>
        <city>Aarhus</city>
        <state>Region Midtjylland</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2017</study_first_submitted>
  <study_first_submitted_qc>March 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2017</study_first_posted>
  <last_update_submitted>December 8, 2017</last_update_submitted>
  <last_update_submitted_qc>December 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myocardial metabolism</keyword>
  <keyword>Positron emission tomography</keyword>
  <keyword>Echocardiography</keyword>
  <keyword>Right sided heart catheterization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Systolic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

